MX2018013227A - Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipr opan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxam ida. - Google Patents
Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipr opan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxam ida.Info
- Publication number
- MX2018013227A MX2018013227A MX2018013227A MX2018013227A MX2018013227A MX 2018013227 A MX2018013227 A MX 2018013227A MX 2018013227 A MX2018013227 A MX 2018013227A MX 2018013227 A MX2018013227 A MX 2018013227A MX 2018013227 A MX2018013227 A MX 2018013227A
- Authority
- MX
- Mexico
- Prior art keywords
- indazol
- methylbutyl
- trifluoromethyl
- hydroxy
- crystalline forms
- Prior art date
Links
- NWFPCWIBSBZRGV-UHFFFAOYSA-N N-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound OC(CCN1N=C2C=C(C(=CC2=C1)NC(=O)C1=NC(=CC=C1)C(F)(F)F)C(C)(C)O)(C)C NWFPCWIBSBZRGV-UHFFFAOYSA-N 0.000 title 1
- OLNRBNUNGHKQJB-UHFFFAOYSA-N 4-[6-(2-hydroxypropan-2-yl)-5-[6-(trifluoromethyl)-2H-pyridin-1-yl]indazol-2-yl]-2-methylbutan-2-ol Chemical compound OC(CCN1N=C2C=C(C(=CC2=C1)N1CC=CC=C1C(F)(F)F)C(C)(C)O)(C)C OLNRBNUNGHKQJB-UHFFFAOYSA-N 0.000 abstract 1
- QKDCLUARMDUUKN-XMMPIXPASA-N 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide Chemical compound N1=C(O[C@H]2CN(CC2)C(=O)C=C)C(CC)=NC(C(N)=O)=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCN(C)CC1 QKDCLUARMDUUKN-XMMPIXPASA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a las formas de N-[2-(3-Hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-iI)-2H-indazol -5-iI]-6-(trifluorometil)piridin-2-carboxamida, a los procesos para su preparación, a las composiciones farmacéuticas que las comprenden y a su uso en el control de trastornos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167649 | 2016-04-29 | ||
| EP16167650 | 2016-04-29 | ||
| PCT/EP2017/059764 WO2017186700A1 (en) | 2016-04-29 | 2017-04-25 | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013227A true MX2018013227A (es) | 2019-02-13 |
Family
ID=58579196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013232A MX2018013232A (es) | 2016-04-29 | 2017-04-25 | Sintesis de indazoles. |
| MX2018013227A MX2018013227A (es) | 2016-04-29 | 2017-04-25 | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipr opan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxam ida. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013232A MX2018013232A (es) | 2016-04-29 | 2017-04-25 | Sintesis de indazoles. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10633365B2 (es) |
| EP (2) | EP3448847A1 (es) |
| JP (2) | JP6916207B2 (es) |
| KR (2) | KR102379948B1 (es) |
| CN (4) | CN118184628A (es) |
| AU (2) | AU2017256659B2 (es) |
| BR (1) | BR112018072247A2 (es) |
| CA (2) | CA3022329A1 (es) |
| CL (2) | CL2018003085A1 (es) |
| CO (2) | CO2018011655A2 (es) |
| CU (1) | CU24593B1 (es) |
| DK (1) | DK3448849T3 (es) |
| DO (1) | DOP2018000236A (es) |
| EA (1) | EA038103B1 (es) |
| EC (1) | ECSP18081451A (es) |
| ES (1) | ES2801800T3 (es) |
| GE (1) | GEP20217230B (es) |
| HU (1) | HUE049331T2 (es) |
| IL (2) | IL262391B (es) |
| JO (2) | JOP20170102B1 (es) |
| LT (1) | LT3448849T (es) |
| MA (1) | MA44758A (es) |
| MX (2) | MX2018013232A (es) |
| NI (1) | NI201800111A (es) |
| PE (2) | PE20190172A1 (es) |
| PH (1) | PH12018502288A1 (es) |
| PL (1) | PL3448849T3 (es) |
| PT (1) | PT3448849T (es) |
| RS (1) | RS60419B1 (es) |
| SG (2) | SG11201809172WA (es) |
| SI (1) | SI3448849T1 (es) |
| SV (1) | SV2018005776A (es) |
| TN (1) | TN2018000359A1 (es) |
| TW (3) | TWI671291B (es) |
| UA (2) | UA122882C2 (es) |
| UY (2) | UY37214A (es) |
| WO (2) | WO2017186693A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| UA123169C2 (uk) | 2016-04-29 | 2021-02-24 | Байєр Фарма Акцієнгезелльшафт | Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду |
| UA122882C2 (uk) | 2016-04-29 | 2021-01-13 | Байєр Фарма Акцієнгезелльшафт | Синтез індазолів |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| SG11201809470RA (en) * | 2016-06-01 | 2018-11-29 | Bayer Animal Health Gmbh | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| JP7511489B2 (ja) | 2018-06-25 | 2024-07-05 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ＩＲＡＫ４阻害薬としてのイソチアゾロ［５，４－ｄ］ピリミジン化合物 |
| KR102392788B1 (ko) | 2019-01-08 | 2022-04-28 | 주식회사 엘지에너지솔루션 | 폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법 |
| CN111499612B (zh) * | 2019-01-30 | 2022-12-30 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
| CN113521079A (zh) * | 2020-04-20 | 2021-10-22 | 上海领泰生物医药科技有限公司 | Irak4抑制剂在治疗ali/ards中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1986643A1 (en) | 2006-02-10 | 2008-11-05 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| US7879887B2 (en) | 2006-06-29 | 2011-02-01 | Nissan Chemical Industries, Ltd. | α-amino acid derivatives and medicaments containing the same as an active ingredient |
| CN101616910A (zh) | 2006-09-07 | 2009-12-30 | 比奥根艾迪克Ma公司 | 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 |
| WO2011043479A1 (ja) | 2009-10-09 | 2011-04-14 | 田辺三菱製薬株式会社 | 脳梗塞治療薬 |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| SI2655357T1 (sl) | 2010-12-20 | 2016-10-28 | Merck Serono S.A. | Derivati indazolil triazola kot zaviralci IRAK |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| WO2014086712A1 (en) * | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| US9126984B2 (en) * | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| KR20160115933A (ko) * | 2014-01-10 | 2016-10-06 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 인다졸 화합물 |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| UY36660A (es) * | 2015-04-30 | 2016-11-30 | Bayer Pharma AG | Combinaciones de inhibidores de irak4 |
| CU20180006A7 (es) | 2015-07-15 | 2018-06-05 | Aurigene Discovery Tech Ltd | Compuestos de indazaol y azaindazol como inhibidores de irak-4 |
| WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| UA122882C2 (uk) | 2016-04-29 | 2021-01-13 | Байєр Фарма Акцієнгезелльшафт | Синтез індазолів |
| UA123169C2 (uk) | 2016-04-29 | 2021-02-24 | Байєр Фарма Акцієнгезелльшафт | Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| SG11201809470RA (en) | 2016-06-01 | 2018-11-29 | Bayer Animal Health Gmbh | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
-
2017
- 2017-04-25 UA UAA201811328A patent/UA122882C2/uk unknown
- 2017-04-25 UA UAA201811327A patent/UA123550C2/uk unknown
- 2017-04-25 JP JP2018556406A patent/JP6916207B2/ja active Active
- 2017-04-25 KR KR1020187030703A patent/KR102379948B1/ko active IP Right Grant
- 2017-04-25 EP EP17718559.2A patent/EP3448847A1/en active Pending
- 2017-04-25 EP EP17719256.4A patent/EP3448849B1/en active Active
- 2017-04-25 CN CN202410286070.1A patent/CN118184628A/zh active Pending
- 2017-04-25 GE GEAP201714932A patent/GEP20217230B/en unknown
- 2017-04-25 JP JP2018556410A patent/JP6821701B2/ja active Active
- 2017-04-25 DK DK17719256.4T patent/DK3448849T3/da active
- 2017-04-25 CU CU2018000130A patent/CU24593B1/es unknown
- 2017-04-25 TN TNP/2018/000359A patent/TN2018000359A1/en unknown
- 2017-04-25 US US16/097,463 patent/US10633365B2/en active Active
- 2017-04-25 MX MX2018013232A patent/MX2018013232A/es unknown
- 2017-04-25 PE PE2018002240A patent/PE20190172A1/es unknown
- 2017-04-25 SG SG11201809172WA patent/SG11201809172WA/en unknown
- 2017-04-25 AU AU2017256659A patent/AU2017256659B2/en active Active
- 2017-04-25 PL PL17719256T patent/PL3448849T3/pl unknown
- 2017-04-25 PE PE2023003161A patent/PE20240651A1/es unknown
- 2017-04-25 WO PCT/EP2017/059748 patent/WO2017186693A1/en active Application Filing
- 2017-04-25 CN CN201780026606.4A patent/CN109071491B/zh active Active
- 2017-04-25 BR BR112018072247-2A patent/BR112018072247A2/pt not_active Application Discontinuation
- 2017-04-25 US US16/097,506 patent/US10501437B2/en active Active
- 2017-04-25 CA CA3022329A patent/CA3022329A1/en active Pending
- 2017-04-25 CN CN202110078561.3A patent/CN112898269A/zh active Pending
- 2017-04-25 WO PCT/EP2017/059764 patent/WO2017186700A1/en active Application Filing
- 2017-04-25 RS RS20200749A patent/RS60419B1/sr unknown
- 2017-04-25 MX MX2018013227A patent/MX2018013227A/es unknown
- 2017-04-25 CA CA3022327A patent/CA3022327A1/en active Pending
- 2017-04-25 ES ES17719256T patent/ES2801800T3/es active Active
- 2017-04-25 LT LTEP17719256.4T patent/LT3448849T/lt unknown
- 2017-04-25 KR KR1020187030702A patent/KR102409105B1/ko active IP Right Grant
- 2017-04-25 AU AU2017257208A patent/AU2017257208B2/en active Active
- 2017-04-25 MA MA044758A patent/MA44758A/fr unknown
- 2017-04-25 CN CN201780040907.2A patent/CN109415339A/zh active Pending
- 2017-04-25 SI SI201730292T patent/SI3448849T1/sl unknown
- 2017-04-25 HU HUE17719256A patent/HUE049331T2/hu unknown
- 2017-04-25 EA EA201892407A patent/EA038103B1/ru unknown
- 2017-04-25 PT PT177192564T patent/PT3448849T/pt unknown
- 2017-04-25 SG SG11201808686VA patent/SG11201808686VA/en unknown
- 2017-04-27 JO JOP/2017/0102A patent/JOP20170102B1/ar active
- 2017-04-27 JO JOP/2017/0101A patent/JOP20170101B1/ar active
- 2017-04-28 TW TW106114179A patent/TWI671291B/zh active
- 2017-04-28 TW TW108120349A patent/TW201936599A/zh unknown
- 2017-04-28 UY UY0001037214A patent/UY37214A/es not_active Application Discontinuation
- 2017-04-28 UY UY0001037217A patent/UY37217A/es active IP Right Grant
- 2017-04-28 TW TW106114181A patent/TWI651316B/zh active
-
2018
- 2018-10-15 IL IL262391A patent/IL262391B/en unknown
- 2018-10-16 IL IL262413A patent/IL262413B/en active IP Right Grant
- 2018-10-26 PH PH12018502288A patent/PH12018502288A1/en unknown
- 2018-10-29 DO DO2018000236A patent/DOP2018000236A/es unknown
- 2018-10-29 SV SV2018005776A patent/SV2018005776A/es unknown
- 2018-10-29 CO CONC2018/0011655A patent/CO2018011655A2/es unknown
- 2018-10-29 NI NI201800111A patent/NI201800111A/es unknown
- 2018-10-29 EC ECSENADI201881451A patent/ECSP18081451A/es unknown
- 2018-10-29 CO CONC2018/0011607A patent/CO2018011607A2/es unknown
- 2018-10-29 CL CL2018003085A patent/CL2018003085A1/es unknown
- 2018-10-29 CL CL2018003097A patent/CL2018003097A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013227A (es) | Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipr opan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxam ida. | |
| SA518400333B1 (ar) | شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد | |
| PH12016502523A1 (en) | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| PH12016501724A1 (en) | Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| PH12016501619A1 (en) | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| MX2016013029A (es) | Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados. | |
| MX2018002446A (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
| PH12019501252A1 (en) | Compositions and methods related to pyridinoylpiperidine 5-htif agonists | |
| PH12016501393B1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| MX2021003064A (es) | Formas cristalinas de 6-(1-acriloilpiperidin-4-il)-2-(4-fenoxifeni l)nicotinamida. | |
| EA201401235A1 (ru) | Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов, её применение и способ лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника |